DRNAX Fees and Costs — BNY Mellon Alternative Diversifier Strategies Fund, Class A
Data updated: 2023-06-28
The net expense ratio is 2.06% (2.38% before fee waivers). This share class carries a maximum front-end sales load of 5.75%. Portfolio turnover was 14%.
DRNAX Fees and Expenses
Annual operating expenses and sales charges of DRNAX. Prospectus, as of October 31, 2022.
| Annual operating expenses | |
|---|---|
| Management fee | 0.25% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.87% |
| Gross expense ratio | 2.38% |
| Fee waiver | −0.32% |
| Net expense ratio | 2.06% |
| Sales charges | |
|---|---|
| Max front load | 5.75% |
| Max deferred load | 0.00% |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | No |
DRNAX Costs Over Time
On $10,000 invested in DRNAX, assuming 5% a year before costs, total costs come to $1,923 over 5 years, cutting the return by 3.37% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Sales charges | $575 | $575 | $575 |
| Fund expenses (net expense ratio 2.06%) | $204 | $629 | $1,079 |
| Lost growth on money paid in costs | $29 | $122 | $269 |
| Total costs | $808 | $1,326 | $1,923 |
| Value after costs | $9,692 | $10,250 | $10,840 |
| Impact on return, per year | 8.08% | 4.17% | 3.37% |
DRNAX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending October 31, 2022.
- Explicit cost rate (commissions ÷ average net assets): —
- Total broker commissions: —
- Bought from dealers (principal trades, not a cost): —
- Portfolio turnover (prospectus): 14%
- Securities lending: none during the year
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.